RMED - RA MEDICAL SYSTM ()

RMEDのニュース

   Ra Medical Systems Announces Pricing of $12.0 Million Upsized Public Offering  2020/07/30 15:46:00 Business Wire
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (“Ra Medical”) (NYSE: RMED), a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases, today announced that it has priced a public offering of an aggregate of 34,285,714 shares of common stock (or common stock equivalents), together with accompanying warrants to purchase up to an aggregate of 34,285,714 sh
   The Law Offices of Frank R. Cruz Announces Investigation of Ra Medical Systems, Inc. (RMED)  2020/06/24 17:23:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $RMED #classaction--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Ra Medical Systems, Inc. (“Ra Medical” or the “Company”) (NYSE: RMED) concerning whether the board breached its fiduciary duty to shareholders. If you are a shareholder, click here for more information. Follow us for updates on Twitter: twitter.com/FRC_LAW. If you purchased Ra Medical securities, have information or would like to learn more about these claims, or ha
   Ra Medical Systems Announces Closing of $10.0 Million Public Offering  2020/05/22 19:23:00 Business Wire
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems completes $10 million financing.
   Ra Medical Systems Receives Continued Listing Standard Notice from the NYSE  2020/05/22 10:50:00 Business Wire
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (“Ra Medical”) (NYSE: RMED), a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases, today announced receipt of written notice from The New York Stock Exchange (the “NYSE”) indicating that Ra Medical is no longer in compliance with the NYSE’s continued listing standards as set forth in Section 802.01C of
   The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive  2020/05/21 12:01:32 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on May 20.) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Ascendis Pharma A/S (NASDAQ: ASND ) (announced first-quarter results) Altimmune Inc (NASDAQ: ALT ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Cue Biopharma Inc (NASDAQ: CUE ) (reacted to first-quarter results) Evoke Pharma Inc (NASDAQ: EVOK ) (announced FDA's conditional approval for the brand name Gimoti for its nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis) GENMAB A/S/S ADR (NASDAQ: GMAB ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Novo Nordisk A/S (NYSE: NVO ) PDL BioPharma Inc (NASDAQ: PDLI ) Pulmatrix Inc (NASDAQ: PULM ) Qiagen NV (NYSE: QGEN ) Soleno Therapeutics Inc (NASDAQ: SLNO ) Surface Oncology Inc (NASDAQ: SURF ) - announced an oncology partnership with Merck & Co., Inc. (NYSE: MRK ) VBI Vaccines Inc (NASDAQ: VBIV ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) (announced $20-million Series A financing to establish a Chinese joint venture) Down In The Dumps (Biotech stocks that hit 52-week lows on May 20.) Genfit SA (NASDAQ: GNFT ) RA Medical Systems Inc (NYSE: RMED ) (priced its 22.22-million-share common stock offering at 45 cents per share) Stocks In Focus Gilead-Galapagos Drug Produces Mixed Results In Ulcerative Colitis Study Gilead Sciences, Inc. (NASDAQ: GILD ) and GALAPAGOS NV/S ADR (NASDAQ: GLPG ) announced top-line results from the Phase 2b/3 trial evaluating the efficacy and safety of filgotinib in adult patients with moderately to severely active ulcerative colitis showing mixed results.
   Ra Medical Systems Announces Pricing of $12.0 Million Upsized Public Offering  2020/07/30 15:46:00 Business Wire
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (“Ra Medical”) (NYSE: RMED), a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases, today announced that it has priced a public offering of an aggregate of 34,285,714 shares of common stock (or common stock equivalents), together with accompanying warrants to purchase up to an aggregate of 34,285,714 sh
   The Law Offices of Frank R. Cruz Announces Investigation of Ra Medical Systems, Inc. (RMED)  2020/06/24 17:23:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $RMED #classaction--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Ra Medical Systems, Inc. (“Ra Medical” or the “Company”) (NYSE: RMED) concerning whether the board breached its fiduciary duty to shareholders. If you are a shareholder, click here for more information. Follow us for updates on Twitter: twitter.com/FRC_LAW. If you purchased Ra Medical securities, have information or would like to learn more about these claims, or ha
   Ra Medical Systems Announces Closing of $10.0 Million Public Offering  2020/05/22 19:23:00 Business Wire
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems completes $10 million financing.
   Ra Medical Systems Receives Continued Listing Standard Notice from the NYSE  2020/05/22 10:50:00 Business Wire
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (“Ra Medical”) (NYSE: RMED), a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases, today announced receipt of written notice from The New York Stock Exchange (the “NYSE”) indicating that Ra Medical is no longer in compliance with the NYSE’s continued listing standards as set forth in Section 802.01C of
   The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive  2020/05/21 12:01:32 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on May 20.) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Ascendis Pharma A/S (NASDAQ: ASND ) (announced first-quarter results) Altimmune Inc (NASDAQ: ALT ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Cue Biopharma Inc (NASDAQ: CUE ) (reacted to first-quarter results) Evoke Pharma Inc (NASDAQ: EVOK ) (announced FDA's conditional approval for the brand name Gimoti for its nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis) GENMAB A/S/S ADR (NASDAQ: GMAB ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Novo Nordisk A/S (NYSE: NVO ) PDL BioPharma Inc (NASDAQ: PDLI ) Pulmatrix Inc (NASDAQ: PULM ) Qiagen NV (NYSE: QGEN ) Soleno Therapeutics Inc (NASDAQ: SLNO ) Surface Oncology Inc (NASDAQ: SURF ) - announced an oncology partnership with Merck & Co., Inc. (NYSE: MRK ) VBI Vaccines Inc (NASDAQ: VBIV ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) (announced $20-million Series A financing to establish a Chinese joint venture) Down In The Dumps (Biotech stocks that hit 52-week lows on May 20.) Genfit SA (NASDAQ: GNFT ) RA Medical Systems Inc (NYSE: RMED ) (priced its 22.22-million-share common stock offering at 45 cents per share) Stocks In Focus Gilead-Galapagos Drug Produces Mixed Results In Ulcerative Colitis Study Gilead Sciences, Inc. (NASDAQ: GILD ) and GALAPAGOS NV/S ADR (NASDAQ: GLPG ) announced top-line results from the Phase 2b/3 trial evaluating the efficacy and safety of filgotinib in adult patients with moderately to severely active ulcerative colitis showing mixed results.
   Ra Medical Systems Announces Pricing of $12.0 Million Upsized Public Offering  2020/07/30 15:46:00 Business Wire
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (“Ra Medical”) (NYSE: RMED), a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases, today announced that it has priced a public offering of an aggregate of 34,285,714 shares of common stock (or common stock equivalents), together with accompanying warrants to purchase up to an aggregate of 34,285,714 sh
   The Law Offices of Frank R. Cruz Announces Investigation of Ra Medical Systems, Inc. (RMED)  2020/06/24 17:23:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $RMED #classaction--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Ra Medical Systems, Inc. (“Ra Medical” or the “Company”) (NYSE: RMED) concerning whether the board breached its fiduciary duty to shareholders. If you are a shareholder, click here for more information. Follow us for updates on Twitter: twitter.com/FRC_LAW. If you purchased Ra Medical securities, have information or would like to learn more about these claims, or ha
   Ra Medical Systems Announces Closing of $10.0 Million Public Offering  2020/05/22 19:23:00 Business Wire
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems completes $10 million financing.
   Ra Medical Systems Receives Continued Listing Standard Notice from the NYSE  2020/05/22 10:50:00 Business Wire
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (“Ra Medical”) (NYSE: RMED), a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases, today announced receipt of written notice from The New York Stock Exchange (the “NYSE”) indicating that Ra Medical is no longer in compliance with the NYSE’s continued listing standards as set forth in Section 802.01C of
   The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive  2020/05/21 12:01:32 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on May 20.) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Ascendis Pharma A/S (NASDAQ: ASND ) (announced first-quarter results) Altimmune Inc (NASDAQ: ALT ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Cue Biopharma Inc (NASDAQ: CUE ) (reacted to first-quarter results) Evoke Pharma Inc (NASDAQ: EVOK ) (announced FDA's conditional approval for the brand name Gimoti for its nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis) GENMAB A/S/S ADR (NASDAQ: GMAB ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Novo Nordisk A/S (NYSE: NVO ) PDL BioPharma Inc (NASDAQ: PDLI ) Pulmatrix Inc (NASDAQ: PULM ) Qiagen NV (NYSE: QGEN ) Soleno Therapeutics Inc (NASDAQ: SLNO ) Surface Oncology Inc (NASDAQ: SURF ) - announced an oncology partnership with Merck & Co., Inc. (NYSE: MRK ) VBI Vaccines Inc (NASDAQ: VBIV ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) (announced $20-million Series A financing to establish a Chinese joint venture) Down In The Dumps (Biotech stocks that hit 52-week lows on May 20.) Genfit SA (NASDAQ: GNFT ) RA Medical Systems Inc (NYSE: RMED ) (priced its 22.22-million-share common stock offering at 45 cents per share) Stocks In Focus Gilead-Galapagos Drug Produces Mixed Results In Ulcerative Colitis Study Gilead Sciences, Inc. (NASDAQ: GILD ) and GALAPAGOS NV/S ADR (NASDAQ: GLPG ) announced top-line results from the Phase 2b/3 trial evaluating the efficacy and safety of filgotinib in adult patients with moderately to severely active ulcerative colitis showing mixed results.

calendar